Epidemiologic Investigation of Eye Symptoms Related to COVID-19 among Outpatient Population (preprint)

Since 2019, with the spread of the coronavirus and the emergence of new strains around the world, the effects of this virus on various organs of the body have been identified through various studies. According to these studies, the coronavirus has the ability to be transmitted through mucosal membranes, including respiratory membranes such as the nasal and conjunctival membranes. As the eyes are connected to the nasal duct through the inferior meatus, it is possible for the virus to be transmitted through this route. Wearing a mask can reduce the chance of transmission, but it can also lead to eye symptoms such as dryness. Additionally, individuals with COVID-19 experience various symptoms in their body systems. Some of these symptoms can affect the visual system and lead to blurry vision, dry eyes, foreign body sensation, tearing, and more. These symptoms can cause early eye fatigue and reduce the quality of academic and occupational performance. Since there is limited research in this area and considering the importance of this disease and its consequences, we decided to conduct an observational study on a number of COVID-19 patients referred to the clinic.

A Randomized Clinical Trial Comparing N-acetylcysteine and Bromhexine in Outpatients with COVID-19 (preprint)

This study aimed to compare the effects of N-acetylcysteine and Bromhexine on the recovery rate and prevention of hospitalization in outpatients with COVID-19. PCR-confirmed COVID-19 patients were divided into three groups: N-acetylcysteine group, Bromhexine group, and control group. Patients were followed up on the seventh and fourteenth days of the disease, and hospitalization and mortality rates were evaluated after one month. The study found that both N-acetylcysteine and Bromhexine can effectively reduce hospitalization rates and mortality and shorten the duration of hospitalization. The third visit of patients who received N-acetylcysteine showed an increase of 1.33% in oxygen saturation compared to their first visit, and in patients who received Bromhexine, this increase was 1.19%. The mortality rate was 9.33% in the control group and zero in both groups of patients who received medication. This study provides evidence for the early initiation of N-acetylcysteine and Bromhexine in outpatients with COVID-19. Clinical trial code: IRCT20220302054167N1, ethics code: IR.UMSHA.REC.1400.957.